Poster Session A

Poster Session A
Monday, December 3
4:30 p.m.-7:00 p.m.

In alphabetical order, not board assignment order

• A high-throughput RNAi screen unravels new immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. Nisit Khandelwal, German Cancer Research Centre (DKFZ), Heidelberg, Germany
• Active immunotherapy with PROSTVAC® demonstrates potent anti-tumor efficacy in a mouse model of prostate cancer. Ryan Rountree, BN ImmunoTherapeutics (BNIT), Mountain View, CA
• Alpha particles and induction of an anti-tumour immune response. Jean-Baptiste Gorin, Institut de Recherche Thérapeutique de l'Université de Nantes, INSERM UMR S 892 – CRCNA, Nantes, France
• Altered monocyte-derived dendritic cell differentiation in the presence of tumor supernatant: Possible involvement the p38MAPK pathway. Bruna Zelante, Institute of Biomedical Sciences – University of Sao Paulo, Sao Paulo, Brazil
• An Ad5 [E1-, E2b-] platform carrying the TAA CEA(6D) induces CEA-directed CMI responses in patients with advanced CEA-expressing colorectal cancer in a phase I/II clinical trial. Elizabeth Gabitzsch, Etubics Corporation, Seattle, WA
• An IL-17-rich tumor microenvironment promotes tumor growth via stimulation of activation-induced immune exhaustion. Jun Wang, Dalhousie University, Halifax, NS, Canada
• Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer. Lana Kandalaft, University of Pennsylvania, Philadelphia, PA
• Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits anti-tumor immunity against peritoneal dissemination and exhibits safety potentials in mice and monkeys. Masahiro Ohgidani, Kyushu University, Fukuoka, Japan
• Cancer immunotherapy using naked DNA vaccine targeting p53. Rueyshyang Soong, Chang Gung Memorial Hospital, Keelung, Taiwan
• Cisplatin induces CSC phenotype and modulates cytokine production in ovarian cancer cells. Alice Herlinger, RENORBIO/Universidade Federal do Espírito Santo, Vitória, ES, Brazil
• Combination immunotherapy with anti-CD40 mAb and MPL results in T cell-independent antitumor effects against B16 melanoma in mice. Alexander Rakhmilevich, University of Wisconsin, Madison, WI
• Combining early heat shock protein vaccination with directed IL-2 leads to effective and persistent anti-tumor immunity in recipients of experimental autologous hematopoietic cell transplantation. Robert Newman, Sylvester Comprehensive Cancer Center, Miami, FL
• Comparative mRNA and microRNA expression profiling of canine mammary carcinoma cell lines and macrophages grown as a co-culture in vitro. Magdalena Król, Dept. of Physiological Sciences, Fac. of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland
• CTLA-4 blockade improves the balance of CD8+ effector and CD4+ regulatory T cells following adoptive cell transfer melanoma immunotherapy. Clifford Cho, William S. Middleton Memorial VA Hospital, Madison, WI
• Development and characterization of a novel antibody-(IL-12) fusion protein with complete disruption of heparin-binding activity. Rosendo Luria-Pérez, Children’s Hospital of Mexico Federico Gomez, Mexico, and University of California at Los Angeles, Los Angeles, CA
• Disrupted transmigration of neutrophils in glioblastoma patients is augmented by steroid treatment. Trisha Sippel, University of Colorado Anschutz Medical Campus, Aurora, CO
• Distinct roles of type I and type II interferons in radiation-induced antitumor immunity against B16 Melanoma. Joanne Lim, University of Rochester, Rochester, NY
• Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy. Thomas Schmitt, Fred Hutchinson Cancer Research Center, Seattle, WA
• Enabling in vivo visualization of cellular therapies in the clinic: Maturation of αDC1 data sets. Brooke Helfer, Celsense Inc., Pittsburgh, PA
• Enhanced effector responses in CAR-redirected CD8+ T cells deficient in diacylglycerol kinases. Matthew Riese, Medical College of Wisconsin, Milwaukee, WI
• Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4. Aude Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA
• Enhancing chemotherapy efficacy and antitumor immune activity by combined antisense downregulation of TS and IDO. Saman Maleki Vareki, Western University, London, ON, Canada
• Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors. Liang-Chuan Wang, University of Pennsylvania, Philadelphia, PA
• Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma. Nikolai Siebert, University Medicine Greifswald, Greifswald, Germany
• Genetic analysis and therapeutic targeting of IDO pathways in cancer. George Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA
• Genetically engineered T cells redirected against cancer-associated fibroblasts to potentiate immunotherapeutic effects. Sunitha Kakarla, Baylor College of Medicine, Houston, TX
• HER2/neu oncogene-induced tumors in mammary epithelial cell COX-2-deficient mice have disease delaying modifications of tumor microenvironment. Nune Markosyan, University of Pennsylvania, Philadelphia, PA
• HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Simone Gusenbauer, Max Planck Inst. of Biochemistry, Martinsried/Munich, Bavaria, Germany
• Hypochlorous acid-oxidized tumor dendritic cell vaccines are strongly Th1 proinflammatory and prime broad tumor-specificity that prolong disease-free survival in recurrent ovarian cancer patients. Cheryl Chiang, University of Pennsylvania, Philadelphia, PA
• Identification of cytokine network-signaling abnormalities in immune cells from cancer patients. Andrea Miyahira, City of Hope, Duarte, CA
• Identification of factors modulating sensitivity to T cell infiltration in the breast cancer setting via next-generation sequencing. Sally Amos, BC Cancer Agency, Victoria, Canada
• IFN-gamma-inducible protein-10 stimulates intratumoral infiltration of adoptively transferred human NK cells in a melanoma xenograft mouse model. Erik Wennerberg, Karolinska Institutet, Stockholm, Sweden
• IL-33 promotes CD8 T cell effector function and has a potent antitumor activity in vivo. Xin Gao, University of Pittsburgh, Pittsburgh, PA
• Imatinib modulates CD4+ T cells in gastrointestinal stromal tumor (GIST). Vinod Balachandran, Memorial Sloan-Kettering Cancer Center, New York, NY
• Immune-based treatment of ovarian cancer in a mouse model with attenuated Toxoplasma gondii. Steven Fiering, Geisel Medical School at Dartmouth, Hanover, NH
• Immunodominant antigenic repertoire of ex vivo melanoma cells: Interaction with PLX4032. Andrea George, New York Medical College, Valhalla, NY
• Increased levels of IL-12, IL-23, and IL-18 in skin-expressing HPV16 E7 protein. Christina Gosmann, The University of Queensland Diamantina Institute, Brisbane, Qld, Australia
• Inflammatory biomarker c-reactive protein in radiotherapy-induced skin toxicities of breast cancer patients. Jennifer Huang, Sylvester Comprehensive Cancer Center, Department of Epidemiology and Public Health, Miami, FL
• Inhibition of IL-8 production by pancreatic cancer cells with marine natural products. Esther Guzman, Harbor Branch Oceanographic Institute at Florida Atlantic University, Fort Pierce, FL
• Inhibition of the heat shock protein receptor CD91 abrogates concomitant anti-tumor immunity. Robert Binder, University of Pittsburgh, Pittsburgh, PA
• Interactions between dendritic cells and T lymphocytes in a novel 3D environment. Karen Steponavicius-Cruz, ICB-USP, São Paulo, Brazil
• MDSC phenotypes, but not Tregs, predict patient survival in unresectable stage IV melanoma independently of the type of treatment applied. Graham Pawelec, University of Tübingen, Tübingen, Germany
• Melanoma-educated CD14+ monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling. Yumeng Mao, Karolinska Institutet, Stockholm, Sweden
• Metronomic chemotherapy activates innate immunity-induced tumor regression. David Waxman, Boston University, Boston, MA
• Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in Vk*MYC mice. Arianna Calcinotto, Istituto Scientifico San Raffaele, Milan, Italy
• Mouse models of autochthonous cancer to study local immune subversion. Ali Bransi, University Hospital Zurich, Zurich, Switzerland
• Myofibroblasts activated upon tissue injury and hypoxia promote development of castration-resistant prostate cancer. Massimo Ammirante, University of California, San Diego, La Jolla, CA
• Neutrophils recruit T-regulatory cells into the tumor via secretion of CCL17: A new mechanism of tumor-immune surveillance. Inbal Mishalian, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
• NK cell activation and cytotoxicity can be enhanced with chemotherapy in a murine model of glioblastoma. Serena Pellegatta, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
• Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer. Christian Klein, Roche Glycart AG, Schlieren, Switzerland
• Oncogenic driver mutations shape the nature of immune responses in tumors. Vladislava Juric, University of California, San Francisco, San Francisco, CA
• Overcoming therapeutic MAb resistance in aggressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells. Sandrine Valsesia-Wittmann, Centre Leon Berard, Lyon, France
• Patterns and kinetics of interferon-γ secretion by natural killer cell subsets co-cultured with cetuximab-coated head and neck cancer cells and dendritic cells. Christopher Lord, University of Pittsburgh School of Medicine, Pittsburgh, PA
• PD-1 blockade during vaccination stimulates tumor infiltration of memory precursor T cells and fosters complete tumor regression. Lavakumar Karyampudi, Mayo Clinic, Rochester, MN
• Peripheral Blood Monocytes Predict Survival in Pancreatic Cancer. Dominic Sanford, Washington University in St. Louis, St. Louis, Missouri
• Potent Th cell epitope-modified HER2/neu dendritic cell vaccine magnifies anti-tumor responses in HER2/neu tolerance transgenic mice. Yuxiu Chen, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
• Potential immunotherapeutic strategies in well differentiated retroperitoneal liposarcoma based on the naturally occurring, intratumoral immune response. William Tseng, The University of Texas MD Anderson Cancer Center, Houston, TX
• Preclinical models to study tumor-infiltrating chimeric antigen receptor-expressing lymphocyte hypofunction in adoptive T cell therapy (ACT). Edmund Moon, University of Pennsylvania, Philadelphia, PA
• Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development. Bridget Keenan, Johns Hopkins School of Medicine, Baltimore, MD
• Prognostic value of CD8 and FoxP3 positive T-lymphocytes at the tumor-invasive front of colorectal cancer. Agnes Ling, Dept. Medical Biosciences, Pathology, Umeå, Sweden
• Reconditioning the tumor-immune microenvironment for a breast cancer vaccine therapy. Yuhui Huang, Massachusetts General Hospital and Harvard Medical School, Boston, MA
• Regulation of the breast tumor microenvironment by interferon regulatory factor 5 (IRF5). Erica Pimenta, University of Medicine and Dentistry of New Jersey, Rahway, NJ
• Role of Myeloid SOCS3 in Prostate Cancer Progression. Hao Yu, University of Alabama at Birmingham, Birmingham, AL
• Significantly targeting rituximab-resistant B cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells. Mitchell Cairo, New York Medical College, Valhalla, New York
• Splenectomy inhibits tumor development and metastases in murine lung cancer models. Zvi Fridlender, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
• Sunitinib augments oncolytic reovirus mediated anti-tumor immunity in an immunocompetent murine model of renal cell carcinoma. Keith Lawson, University of Calgary, Calgary, Alberta, Canada
• Suppression of H-Ras activity enhances TRAIL-induced apoptosis through upregulation of cell surface expression of death receptor 5. Jun-Jie Chen, Division of Therapeutic Proteins, Office of Biotechnology Products, CDER/FDA, Bethesda, MD
• T cell anti-tumor responses triggered by activated B lymphocytes. Ana Paula Lepique, Institute of Biomedical Sciences São Paulo, São Paulo, Brazil
• T cell costimulation by TNFRSF4, TNFRSF18, and TNFRSF25 in the context of vaccination. Taylor Schreiber, University of Miami Miller School of Medicine, Miami, FL
• Targeting costimulation to the tumor stroma with bispecific oligonucleotide aptamers. Brett Schrand, University of Miami Miller School of Medicine, Miami, FL
• Targeting prostate stem cell antigen (PSCA) with CAR-engineered T cells. Victoria Hillerdal, Uppsala University, Uppsala, Sweden
• Targeting tumor-associated macrophages with a humanized anti-CSF1R antibody: A novel approach for anti-tumor therapy. Valeria Runza, Roche Pharma Research and Early Development, Penzberg, Germany
• TARP-TCR-engineered T cells specifically kill HLA-A2-positive prostate and breast cancer cells. Magnus Essand, Uppsala University, Uppsala, Sweden
• The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. Russell Pachynski, Stanford University, Stanford, CA
• The genetic adjuvant DAI promotes CD8+ T cell responses in DNA vaccination. Helena Tufvesson, Karolinska Institutet, Stockholm, Sweden
• The novel strategy for treatment of pancreatic ductal adenocarcinoma targeting tumor microenvironment. Motohisa Tada, Chiba University, Chiba, Japan
• The number of MDSC (Gr1+/CD11b+) and T lymphocytes in blood of canine patients during mammary and skin tumors development. Magdalena Król, Dep.of Physiological Sciences, Fac.of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland
• The selective recruitment and retainment of regulatory T cells in human colorectal cancer. Stephen Ward, University of Birmingham, Birmingham, England
• The synergy between IL-12 priming of CD8 T cells and lymphodepletion is mediated by host IL-7. Christopher Johnson, Medical University of South Carolina, Charleston, SC
• Therapeutic efficacy of anti-tumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells. Yvonne Saenger, Mount Sinai School of Medicine, New York, NY
• Toll-like receptor 3 signaling in ovarian cancer. Maria Muccioli, Ohio University, Athens, Ohio
• Transforming growth factor-beta (TGF-ß) gene silencing using adenovirus expressing TGF-ß1 or TGF-ß2 shRNA. Jina Kim, Institute for Cancer Research, Yonsei University, Seoul, Korea (Rep.)
• Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Zvi Fridlender, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
• Tumor-suppressive function of human macrophage-derived ADAM15 exosomes. Doo-Sik Kim, Yonsei University, Seoul, Korea (Rep.)
• VAP-1 expression is significantly reduced in colorectal cancer compared to normal colon tissue despite elevated sVAP-1 levels. Stephen Ward, University of Birmingham, Birmingham, England
• Young women's breast cancer demonstrates increased immune suppression through circulating regulatory T cells and myeloid derived supressor cells independent of stage or subtype. Virginia Borges, University of Colorado Denver, Aurora, CO